Decentralized and Digital Clinical Research in Pharmacology: Opportunities and Challenges

Abstract

Pharmacological trials are changing from traditional, site-centric methods to more adaptable, patient-focused strategies as a result of the rise of decentralized and digital clinical research. These models present a once-in-a-lifetime chance to revolutionize drug development by utilizing advancements like wearable sensors, telemedicine, electronic consent, remote monitoring, and mobile health apps. Decentralized clinical trials (DCTs) increase the speed and relevancy of clinical insights by facilitating the enrollment of patients from a wider range of demographics, lowering logistical costs, and enabling the real-time collecting of real-world data. This development has the potential to improve participant retention and compliance while drastically cutting trial durations and operating expenses. But there are challenges associated with this paradigm change. Navigating a changing global regulatory environment, protecting data privacy and integrity, closing the digital literacy gap, and building dependable technology infrastructure across diverse populations and geographical areas are some of the major issues. Furthermore, considerable preparation and supervision are needed to ensure that remotely performed trials respect ethical norms and scientific rigor. The dual nature of these developments is critically examined in this review, which emphasizes both the intricate obstacles and the transformational advantages. To get past these obstacles and realize the full potential of decentralized and digital approaches in pharmaceutical research, stakeholders must take a calculated, cooperative approach.